Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy [1]

Bone Marrow Transplantation

Volumn 38, Issue 6, 2006, Pages 461-462

  Milojkovic D ^a   Aldouri, M ^b   Pagliuca, A ^a   Mufti, G J ^a   Devereux, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE ABDOMEN; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW BIOPSY; CASE REPORT; CHOLECYSTITIS; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC DUCT; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LAPAROTOMY; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; LONG TERM CARE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PARENTERAL NUTRITION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE TRANSFUSION; MELPHALAN; PODOPHYLLOTOXIN; PREDNISONE; REMISSION INDUCTION; TIME FACTORS; VINCRISTINE;

EID: 33748424120     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705469     Document Type: Letter

References (5)

1. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: Integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
2. Tsimberidou AM, Keating MJ. Richter syndrome: Biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216-228.
3. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
4. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602.
5. Rodriguez J, Keating MJ, O'Brien S, Champlin RE, Khouri IF. Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 2000; 110: 897-899.